Literature DB >> 20592110

Modification of the major tegument protein pp65 of human cytomegalovirus inhibits virus growth and leads to the enhancement of a protein complex with pUL69 and pUL97 in infected cells.

Sabine Becke1, Véronique Fabre-Mersseman, Steffi Aue, Sabrina Auerochs, Tina Sedmak, Uwe Wolfrum, Dennis Strand, Manfred Marschall, Bodo Plachter, Sabine Reyda.   

Abstract

The tegument protein pp65 of human cytomegalovirus (HCMV) is abundant in lytically infected human foreskin fibroblasts (HFF), as well as in virions and subviral dense bodies (DB). Despite this, we showed previously that pp65 is dispensable for growth in HFF. In the process of refining a DB-based vaccine candidate, different HCMV mutants were generated, expressing a dominant HLA-A2-presented peptide of the IE1 protein fused to pp65. One of the mutant viruses (RV-VM1) surprisingly showed marked impairment in virus release from HFF. We hypothesized that analysis of the phenotypic alterations of RV-VM1 would provide insight into the functions of pp65, poorly defined thus far. RV-VM1 infection resulted in nuclear retention of the fusion protein and reorganization of nuclear inclusion bodies. Coimmunoprecipitation experiments suggested that wild-type (wt) pp65 and pp65-VM1 were substrates of the viral pUL97 kinase in vitro and formed a complex with the viral RNA-export protein pUL69 and with pUL97 in lysates of infected cells. No evidence for an impairment of pUL97 within this complex was found. However, RV-VM1 replication in infected cells was resistant to a pUL97 inhibitor, and pUL97 inhibitors mimicked the mutant in terms of pp65 being retained in the nucleus. The results suggest that the life cycle of RV-VM1 was impeded at the stages of early-late transcription, RNA export or capsid maturation. wt-pp65 may play a role at these stages of infection, and complex formation with pUL69 and pUL97 may be important for that function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20592110     DOI: 10.1099/vir.0.022293-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.

Authors:  Sunwen Chou; Ronald J Ercolani; Gail Marousek; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

2.  Nucleocytoplasmic shuttling and CRM1-dependent MHC class I peptide presentation of human cytomegalovirus pp65.

Authors:  Nadine Frankenberg; Peter Lischka; Sandra Pepperl-Klindworth; Thomas Stamminger; Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2012-09-11       Impact factor: 3.402

3.  A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations.

Authors:  Corina Hutterer; Jan Eickhoff; Jens Milbradt; Klaus Korn; Isabel Zeitträger; Hanife Bahsi; Sabrina Wagner; Gunther Zischinsky; Alexander Wolf; Carsten Degenhart; Anke Unger; Matthias Baumann; Bert Klebl; Manfred Marschall
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

4.  The tegument protein pp65 of human cytomegalovirus acts as an optional scaffold protein that optimizes protein uploading into viral particles.

Authors:  Sabine Reyda; Stefan Tenzer; Pedro Navarro; Wolfgang Gebauer; Michael Saur; Steffi Krauter; Nicole Büscher; Bodo Plachter
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

5.  Cyclins B1, T1, and H differ in their molecular mode of interaction with cytomegalovirus protein kinase pUL97.

Authors:  Mirjam Steingruber; Lena Keller; Eileen Socher; Sabrina Ferre; Anne-Marie Hesse; Yohann Couté; Friedrich Hahn; Nicole Büscher; Bodo Plachter; Heinrich Sticht; Manfred Marschall
Journal:  J Biol Chem       Date:  2019-02-19       Impact factor: 5.157

6.  Human cytomegalovirus UL97 kinase and nonkinase functions mediate viral cytoplasmic secondary envelopment.

Authors:  Miri D Goldberg; Alik Honigman; Jacob Weinstein; Sunwen Chou; Albert Taraboulos; Alexander Rouvinski; Vera Shinder; Dana G Wolf
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

7.  Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.

Authors:  Rike Webel; Morgan Hakki; Mark N Prichard; William D Rawlinson; Manfred Marschall; Sunwen Chou
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

8.  The Abundant Tegument Protein pUL25 of Human Cytomegalovirus Prevents Proteasomal Degradation of pUL26 and Supports Its Suppression of ISGylation.

Authors:  Christine Zimmermann; Nicole Büscher; Steffi Krauter; Nadine Krämer; Uwe Wolfrum; Elisabeth Sehn; Stefan Tenzer; Bodo Plachter
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

9.  Antiviral Drugs Against Herpesviruses.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Regulatory Interaction between the Cellular Restriction Factor IFI16 and Viral pp65 (pUL83) Modulates Viral Gene Expression and IFI16 Protein Stability.

Authors:  Matteo Biolatti; Valentina Dell'Oste; Sara Pautasso; Jens von Einem; Manfred Marschall; Bodo Plachter; Marisa Gariglio; Marco De Andrea; Santo Landolfo
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.